

AMENDMENTS TO THE CLAIMS

This Listing of Claims will replace all prior versions and listings of claims in this application.

Please cancel claims 18 and 19 without prejudice or disclaimer.

Listing of Claims:

1. (Currently Amended) A fat and oil processed composition for prevention and/or amelioration of a life-style related disease, in which at least one compound selected from the group consisting of glabrene, glabridin, glabrol, 3'-hydroxy-4'-O-methylglabridin, 4'-O-methylglabridin and hypaglabridin B or a salt, an ester or a glycoside thereof is dissolved in the fat and oil, wherein the total amount of the at least one compound is about 0.01 to 30% by weight based on the composition, and the fat and oil contains at least about 50% by weight of a medium-chain fatty acid triglyceride having a viscosity of about 23 to 28 cP at about 20°C.
2. (Cancelled)
3. (Cancelled)
4. (Previously Presented) The fat and oil processed composition according to claim 1, in which at least one compound selected from the group consisting of glabrene, glabridin, glabrol, 3'-hydroxy-4'-O-methylglabridin, 4'-O-methylglabridin and hypaglabridin B or a salt, an ester or a glycoside thereof is contained in such an amount that about 0.01 to 10 mg/kg body weight per adult a day may be ingested in total of the at least one compound.
5. (Previously Presented) The fat and oil processed composition according to claim 1, wherein the fat and oil further comprises a partial glyceride.

6. (Previously Presented) The fat and oil processed composition according to claim 1, wherein the fat and oil comprises a glycerin fatty acid ester containing a medium-chain fatty acid triglyceride in an amount of about 50% by weight or more.
7. (Cancelled)
8. (Previously Presented) The fat and oil processed composition according to claim 1, wherein the life-style related disease comprises at least one member selected from the group consisting of visceral fat obesity, type 2 diabetes, hyperlipemia, and hypertension.
9. (Previously Presented) The fat and oil processed composition according to claim 1, wherein the life-style related disease is visceral fat obesity and/or type 2 diabetes.
10. (Previously Presented) A food or a drink comprising the fat and oil processed composition according to claim 1.
11. (Previously Presented) A pharmaceutical preparation comprising the fat and oil processed composition according to claim 1.
12. (Previously Presented) A cosmetic comprising the fat and oil processed composition according to claim 1.
13. (Previously Presented) A soft capsule formulation comprising the fat and oil processed composition according to claim 1 encapsulated therein.
14. (Previously Presented) The soft capsule formulation according to claim 13, wherein the capsule comprises at least one compound selected from the group consisting of glabrene, glabridin, glabrol, 3'-hydroxy-4'-O-methylglabridin, 4'-O-methylglabridin and hypaglabridin B or a salt, an ester or a glycoside thereof in a total amount of about 0.01 to 150 mg per capsule.

15. (Previously Presented) The fat and oil processed composition according to claim 1, wherein the at least one compound selected from the group consisting of glabrene, glabridin, glabrol, 3'-hydroxy-4'-O-methylglabridin, 4'-O-methylglabridin and hypaglabridin B or a salt, an ester or a glycoside thereof is obtained from *Glycyrrhiza glabra*.
16. (Previously Presented) A process for producing the composition according to claim 1, which comprises dissolving at least one compound selected from the group consisting of glabrene, glabridin, glabrol, 3'-hydroxy-4'-O-methylglabridin, 4'-O-methylglabridin and hypaglabridin B or a salt, an ester or a glycoside thereof in a fat and an oil.
17. (Previously Presented) A method for prevention and/or amelioration of a life-style related disease, which comprises administering an effective amount of the composition according to claim 1 to a mammal subject in need thereof.
- 18-19. (Cancelled)